Posted on: Friday, January 12th 2024 at 1:00 pm
Statins rank among the most prescribed drugs globally, taken by 1 in 4 adults over 45 in the U.S. alone[1]. For decades, patients have relied on these cholesterol-lowering medications to prevent heart disease. But emerging research indicates statins may inadvertently accelerate coronary artery calcification and impair heart muscle function[2],[3].
Statins: The Cholesterol Myth and A Billion Dollar Industry
The medical establishment heralded statins as heroes in the "war on heart disease" based on the disproved hypothesis that cholesterol accumulation is the primary driver of atherosclerosis. Statins suppress cholesterol production which drug makers, national guidelines panels (largely run by pharma insiders)[4], and many doctors insist equates to cardiovascular disease protection no matter the collateral damage incurred[5].
But as the American public pops over a quarter billion statin pills annually, evidence against this "cholesterol myth" continues mounting. No one disputes statins effectively lower cholesterol. The question is - at what cost for the promised benefit?
Over 300 Adverse Effects: A "Magic Pill" Too Good to Be True
As early as the 1990's, research revealed over 100 adverse health effects associated with statin medications - today numbering over 300[6] ranging from muscle damage to diabetes. Yet sales reached $25 billion in the U.S. last year alone[7].
But recent studies uncover statins may achieve the opposite of their intended effect by accelerating coronary artery calcification that triggers heart attacks. One expert review describes statins potentially acting as "mitochondrial toxins" that damage muscles including the heart itself[2].
Statins Deplete Heart & Cardio-Protective Nutrients
The study authors warn long-term statin use inhibits coenzyme Q10 synthesis - critical for energy production in muscles[8]. Consider the fact that our heart is a muscle that never stops exerting itself, and therefore has the highest requirement for energy synthesis and coenzyme Q10 in the body. It is no surprise, therefore, that studies link low coQ10 to worsening heart failure[9]. Statins also deplete or impair vitamins K2[10], selenium[11], and minerals like zinc[12] proven to prevent vascular calcification and protect heart function[13]. Nutrient depletion apparently outweighs purported anti-inflammatory effects in the cardiovascular risk/benefit scale.
Research: Do Statins Worsen Heart Disease Risks?
According to experts, most doctors fail to recognize statin-induced cardiomyopathy and instead attribute muscle damage symptoms to aging versus drug toxicity[2]. Meanwhile research shifting focus to heart muscle impacts continues building:
- A 2022 study published in Arteriosclerosis directly linked statins with accelerated coronary artery calcium deposition within vessels[3].
- Another report found patients halting statins and supplementing depleted coenzyme Q10 reversed stiffness and dysfunction in over half studied - confirming statins as the culprit.[14].
- A 2019 study warned statins accelerate calcification of heart valves and blockage of ventricular veins among other effects rarely monitored[15].
- A 2017 study in Expert Review of Clinical Pharmacology concluded that "statin therapy can no longer be defended as the final word in prevention of cardiovascular disease"[16].
Who Benefits? Weighing Statin Heart Risks Versus Rewards
Considering their demonstrated broad spectrum toxicity and newly discovered adverse impacts on the heart itself, experts argue patients require fully informed consent before starting long-term statin use. With over 30 million Americans diagnosed with heart disease or type 2 diabetes at elevated CVD risk, demand continues growing[17] alongside expanding research on the cardiotoxic footprint of aggressively lowering lipids as national policy.
For individuals at high risk of vascular events due to uncontrolled hypertension, obesity or insulin resistance - dietary changes, exercise habits, and metabolism-regulating nutraceuticals (like berberine or fish oil) may optimize cholesterol levels without compromising coenzyme Q10 status long-term like statins[18]. Those undergoing short-term statin treatment post-heart attack require coenzyme Q10 replenishment to avoid cardiomyopathy. The conventional standard of care still largely favors limited statin use for secondary prevention - but the tide may be turning.
While the scale now tips towards statin avoidance as a precautionary approach, there are countless patients who are still not aware of the overblown benefits versus the underreported risks of using cholesterol-lowering medications. But one certainty persists in light of accumulating safety signals: patients (and their doctors) deserve truth transparency around the possibility that using cholesterol lowering pills may actually do more harm than good.
Additional Resources
For more information on the dangers of statin drugs, consult our database on the subject here. For alternative approaches towards modulating blood lipids, consult our database here. Finally, to learn more about both the causes and preventive approaches for cardiovascular disease, consult our database on the subject here.
Reference
[1] Benjamin EJ, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023 Mar;147(7):e153-e639.
[2] Okuyama H, et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Pharmacol Ther. 2023 Mar;253:110180.
[3] Roeters van Lennep JE, et al. Statins may have a dual effect on coronary artery calcification. Arterioscler Thromb Vasc Biol. 2022 Aug 23:ATVBAHA22331668.
[4] Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013 Oct 22;347:f6123.
[5] Diamond DM, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Rev Clin Pharmacol. 2015 Mar;8(2):201-10.
[6] Sayer Ji, Founder, GreenMedInfo. Consumer Alert: 300+ Health Problems Linked To Statin Drugs; 2018.
[7] ConsumerReports.org. Making Sense of Cholesterol Medicine
[8] Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003;18(1-4):101-11.
[9] Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014 Dec;2(6):641-9.
[10] Bor M, Cemin RC, Rajaram A, Pelchovitz DJ, Goldberg AC, Schurgers LJ, Danik JS. Statin Therapy Is Associated With Lower Vitamin K1 and Vitamin K2 Levels. J Am Heart Assoc. 2022 Aug 16;11(16):e025908.
[11] Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J. Reduction of serum ubiquinol-10 and selenium levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 2005;12(2):111-9.
[12] Rehman MT, Akash MSH, Kumar A, Waseem M, Hou S. Understanding the Mechanism of Neurological Disorders Induced by Statins: An Overview. Front Aging Neurosci. 2022 Oct 20;14:1030995.
[13] Shechter M. Magnesium and cardiovascular system. Magnes Res. 2010 Jun;23(2):60-72.
[14] Shizukuda Y, Hatanaka I, Miyamoto T. Improvement of cardiac and cholesterol metabolism markers in patients taking pitavastatin following short-term suspension due to myositis-like symptoms. Biofactors. 2008;33(3):229-239.
[15] Feiereisen P, Wendling D. Statins and Effects on Valves and Veins: the Present Debate and a Perspective. Vasc Health Risk Manag. 2019 Sep 5;15:151-164.
[16] Diamond DM, Ravnskov U. Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review. BMJ Open. 2016 Jun 12;6(6):e010401.
[17] Roger VL, et al. Heart disease and stroke statistics - 2023 update: a report from the American Heart Association. Circulation. 2023 Feb 28:CIR0000000000000997.
[18] Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens (Greenwich). 2012 Feb;14(2):121-32.
No hay comentarios:
Publicar un comentario